Studio Royal Ancient Oats™ (RAO)
Impatto dei Royal Ancient Oats™ sulla Risposta Glicemica e sugli Enzimi Digestivi
Evaluating the effects of high avenanthramide ancient oat (Royal Ancient Oats™) muffins versus conventional oat muffins in regard to glycemic control.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This study is a randomized, two-period crossover trial with a run-in control baseline and repeated measures, designed to evaluate the effects of high avenanthramide ancient oat (Royal Ancient Oats™) muffins versus conventional oat muffins on glycemic control and related metabolic parameters. A total of 38 non-diabetic adults (HbA1c < 5.7%), who are either overweight (BMI 25-29.9) or obese (BMI ≥ 30) will start with a repeated measures baseline using regular flour (white wheat) muffins for three consecutive days. Following this, participants will be divided into two groups: 19 in the conventional oat muffin group and 19 in the Royal Ancient Oats™ muffin group. This sample size provides 90% power to detect a difference in AUC of at least 20% between treatments, with a two-sided alpha of 0.05.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Kannapolis, North Carolina, Stati Uniti, 28081
- Reclutamento
- Standard Process Nutrition Innovation Center
-
Investigatore principale:
- Chinmayee Panda, PhD
-
Contatto:
- Brea Nance
- Numero di telefono: 2624956410
- Email: spclinic@standardprocess.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Non-diabetic (HbA1c<5.7%) adults both men and women between the ages of 35-65 years with body mass index (BMI) ranging from 25 to 30 kg/m2
- Participants who meet the inclusion criteria will be screened prior to starting the study and must be able to adhere to the requirements of the study.
- Willing to comply with study procedures and supplement regimens.
- Providing consent to participate in the study.
- Willing to limit/minimize foods that are rich sources of fiber and high carb content.
- Participants should avoid taking any non-prescription/over-the-counter medications or nutritional supplements that could influence glycemic response. This includes vitamins, herbal supplements, and any medications affecting metabolism. Examples include probiotics and prebiotics, vit D, vit B12, Ginseng, fenugreek, weight loss supplements like green tea extract and Garcinia cambogia, fiber supplements like inulin and Psyllium husk. If participants need to make any changes due to health reasons, they should consult with the study coordinator before doing so.
Exclusion Criteria:
- Participants who have experienced weight loss or gain exceeding 5% of their body weight in the past 3 months, including those involved in any weight loss or weight gain programs through diet and/or lifestyle changes.
- Participants currently taking medications that could alter metabolism, such as weight loss medications, anti-hypertensive drugs, or lipid-lowering medications.
- Participants with any chronic metabolic diseases, including diabetes, or those using supplements other than a daily multivitamin.
- Pregnant or lactating women will be excluded from the study.
- Participants who use tobacco products.
- Participants who are unwilling to limit or minimize foods that are rich sources of fiber and high carbohydrate content.
- Excessive alcohol consumption (e.g., more than two drinks per day for men and more than one drink per day for women)
- Inconsistency in recent or planned changes in non-prescription/over-the-counter medications or nutritional supplements affecting glycemic response, including vitamins (e.g., Vitamin D, Vitamin B12), herbal supplements (e.g., Ginseng, Fenugreek), weight loss supplements (e.g., green tea extract, Garcinia cambogia), fiber supplements (e.g., inulin, psyllium husk), and probiotics/prebiotics.
- Inability or unwillingness to maintain the current regimen of these medications and supplements throughout the study period without consulting the study coordinator.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: A: Order of receiving muffins differs
A: Order of receiving muffins differs |
muffins made with Royal Ancient Oat Flour™ |
|
Sperimentale: B: Order of receiving muffins differs
B: Order of receiving muffins differs |
muffins made with Royal Ancient Oat Flour™ |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To compare the effect of consuming high avenanthramide Royal Ancient Oats™ muffins or conventional oat muffins versus white wheat flour muffins on postprandial glycemic response.
Lasso di tempo: 2 weeks
|
Area Under the Curve (AUC) for glucose levels over 24 hours, as measured by Continuous Glucose Monitoring (CGM). |
2 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To evaluate the effect of Royal Ancient Oats™ on incretin hormone secretion and satiety hormones.
Lasso di tempo: 2 weeks
|
Subjective measures of hunger and satiety using Visual Analog Scales (VAS). |
2 weeks
|
|
To evaluate the effect of Royal Ancient Oats™ on incretin hormone secretion and satiety hormones.
Lasso di tempo: 2 weeks
|
Changes in GLP-1 levels (pg/mL) |
2 weeks
|
|
To evaluate the effect of Royal Ancient Oats™ on incretin hormone secretion and satiety hormones.
Lasso di tempo: 2 weeks
|
Changes in leptin (pg/mL) |
2 weeks
|
|
To evaluate the effect of Royal Ancient Oats™ on incretin hormone secretion and satiety hormones.
Lasso di tempo: 2 weeks
|
Changes in adiponectin (ng/mL) |
2 weeks
|
|
To evaluate the effect of Royal Ancient Oats™ on incretin hormone secretion and satiety hormones.
Lasso di tempo: 2 weeks
|
Changes in peptide YY (pg/mL) |
2 weeks
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
To evaluate changes in weight, waist circumference, and body composition before and after dietary intervention.
Lasso di tempo: 2 weeks
|
Changes in body weight (kilograms, kg) measured using a calibrated digital scale (InBody) |
2 weeks
|
|
To evaluate changes in weight, waist circumference, and body composition before and after dietary intervention.
Lasso di tempo: 2 weeks
|
Changes in waist circumference (centimeters, cm) measured using a flexible, non-stretchable measuring tape at the midpoint between the lower margin of the last palpable rib and the top of the iliac crest. |
2 weeks
|
|
To evaluate changes in weight, waist circumference, and body composition before and after dietary intervention.
Lasso di tempo: 2 weeks
|
Changes in body fat percentage (%) as measured by bioelectrical impedance analysis (e.g., InBody). |
2 weeks
|
|
To evaluate changes in weight, waist circumference, and body composition before and after dietary intervention.
Lasso di tempo: 2 weeks
|
Changes in skeletal muscle mass (kg) as measured by bioelectrical impedance analysis (e.g., InBody). |
2 weeks
|
|
To evaluate changes in weight, waist circumference, and body composition before and after dietary intervention.
Lasso di tempo: 2 weeks
|
Changes in visceral fat level (arbitrary units) as measured by bioelectrical impedance analysis (e.g., InBody). |
2 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Zhouyao H, Malunga LN, Chu YF, Eck P, Ames N, Thandapilly SJ. The inhibition of intestinal glucose absorption by oat-derived avenanthramides. J Food Biochem. 2022 Oct;46(10):e14324. doi: 10.1111/jfbc.14324. Epub 2022 Jul 27.
- Chen CY, Milbury PE, Collins FW, Blumberg JB. Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. J Nutr. 2007 Jun;137(6):1375-82. doi: 10.1093/jn/137.6.1375.
- Chen V, Zurbau A, Ahmed A, Khan TA, Au-Yeung F, Chiavaroli L, Blanco Mejia S, Leiter LA, Jenkins DJA, Kendall CWC, Sievenpiper JL. Effect of oats and oat ß-glucan on glycemic control in diabetes: a systematic review and meta-analysis of randomized controlled trials. BMJ Open Diabetes Res Care. 2022 Sep 1;10(5):e002784. doi: 10.1136/bmjdrc-2022-002784. PMCID: PMC9438016.
- Raguindin PF, Adam Itodo O, Stoyanov J, Dejanovic GM, Gamba M, Asllanaj E, Minder B, Bussler W, Metzger B, Muka T, Glisic M, Kern H. A systematic review of phytochemicals in oat and buckwheat. Food Chem. 2021 Feb 15;338:127982. doi: 10.1016/j.foodchem.2020.127982. Epub 2020 Sep 5.
- Loskutov, I. G., Gnutikov, A. A., Blinova, E. V. & Rodionov, A. V. The Origin and Resource Potential of Wild and Cultivated Species of the Genus of Oats (Avena L.). Russ J Genet 57, 642-661 (2021)
- Sood, V. K., Sanadya, S. K., Kumar, S., Chand, S. & Kapoor, R. Health benefits of oat (Avena sativa) and nutritional improvement through plant breeding interventions. Crop Pasture Sci 74, 993-1013 (2022).
- Ociepa, T. The oat gene pools - Review about the use of wild species in improving cultivated oat. Journal of Central European Agriculture 20, 251-261 (2019).
- Pearson, R. W., Aldrich, D. G., H Allaway J E Dawson, J. W. & Gardner E G Heyne F L Patterson, C. O. Oats and Oat Improvement. vol. 4 https://acsess.onlinelibrary.wiley.com/doi/ (1952).
- Coffman, F. A. Oat History, Identification and Classification. (1977).
- Shehzad A, Rabail R, Munir S, Jan H, Fernandez-Lazaro D, Aadil RM. Impact of Oats on Appetite Hormones and Body Weight Management: A Review. Curr Nutr Rep. 2023 Mar;12(1):66-82. doi: 10.1007/s13668-023-00454-3. Epub 2023 Feb 15.
- Llanaj E, Dejanovic GM, Valido E, Bano A, Gamba M, Kastrati L, Minder B, Stojic S, Voortman T, Marques-Vidal P, Stoyanov J, Metzger B, Glisic M, Kern H, Muka T. Effect of oat supplementation interventions on cardiovascular disease risk markers: a systematic review and meta-analysis of randomized controlled trials. Eur J Nutr. 2022 Jun;61(4):1749-1778. doi: 10.1007/s00394-021-02763-1. Epub 2022 Jan 3.
- Wehrli F, Taneri PE, Bano A, Bally L, Blekkenhorst LC, Bussler W, Metzger B, Minder B, Glisic M, Muka T, Kern H. Oat Intake and Risk of Type 2 Diabetes, Cardiovascular Disease and All-Cause Mortality: A Systematic Review and Meta-Analysis. Nutrients. 2021 Jul 26;13(8):2560. doi: 10.3390/nu13082560.
- Stewart D, McDougall G. Oat agriculture, cultivation and breeding targets: implications for human nutrition and health. Br J Nutr. 2014 Oct;112 Suppl 2:S50-7. doi: 10.1017/S0007114514002736.
- Sang S, Chu Y. Whole grain oats, more than just a fiber: Role of unique phytochemicals. Mol Nutr Food Res. 2017 Jul;61(7). doi: 10.1002/mnfr.201600715. Epub 2017 Feb 22.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- SP027
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .